Compare AbbVie Inc (ABBV) vs Goodyear Tire & Rubber Co (GT) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Goodyear Tire & Rubber (GT) trades at $7.02, up 6.53% today, with a bullish technical signal from moving averages and oscillators. The stock shows deep value metrics with P/E of 4.69 and P/B of 0.66, but faces profitability challenges with negative net income margin of -11.64% and ROE of -52.56%. Recent developments include the company's move to the S&P SmallCap 600 and new NASA lunar tire contract, while Q1 2026 earnings beat estimates despite a net loss.

The outlook remains mixed with analyst consensus at Buy (34.62%) and price target of $8.80 offering 25% upside, but persistent operational headwinds and declining revenue trends pose significant risks. Investment opportunity lies in valuation discount and Goodyear Forward program benefits, though weak tire volumes and negative cash flow projections for 2026 require careful monitoring.